C-SLUPYOXLO
mitochondrial function, cellular function, bioactive compounds
modulating
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-SLUP
C-SLUPC-SLUPmitochondrial function, cellular function, bioactive compounds
0-100 chain-logic scale · 15 dimensions · scored on public evidence
The goal of this clinical trial is to evaluate the safety and tolerability of the nutritional supplement Youniqor in healthy older adults. The main questions it aims to answer are: Is Youniqor safe and well tolerated when taken daily by healthy adults aged 60 to 80 years? Are there any adverse events or clinically relevant changes in vital signs or laboratory parameters during the study period? Participants will: Take Youniqor daily for 8 weeks Attend scheduled study visits for safety assessments, including vital signs, blood and urine tests, and electrocardiograms Report any adverse events during the study period
Safe-Age Study: A Safety and Tolerability Study of a Nutritional Supplement in Healthy Older Adults ClinicalTrials.Veeva Search CTV Search for a location Search for trials trials Find clinical trials Close Menu Share Share trial Follow Follow trial Safe-Age Study: A Safety and Tolerability Study of a Nutritional Supplement in Healthy Older Adults (SAFE-AGE) Y YOXLO B.V. Status Enrolling Conditions Aging, Healthy Treatments Dietary Supplement: Youniqor Study type Interventional Funder types Industry Identifier s NCT07442097 SAFE-AGE Take notes View location Contact trial Details and patient eli
Beyond the 900-day rule: Reclaiming healthspan as geroscience's primary goal Beyond the 900-day rule: Reclaiming healthspan as geroscience's primary goal Ageing Res Rev . 2025 Dec:112:102857. doi: 10.1016/j.arr.2025.102857. Epub 2025 Aug 5. Author Stef F Verlinden 1 Affiliation 1 YOXLO B.V., Leiden, Netherlands. Electronic address: [email protected]. PMID: 40774052 DOI: 10.1016/j.arr.2025.102857 Abstract The recently proposed "900-day rule" in mouse aging studies-requiring lifespan extension over ultra-long-lived controls-aims to identify interventions that modulate intrinsic agi
That’s a wrap for the final Life Sciences Café of the year! 🎉 A full room, conversations, and a reminder that the strength of this community comes from people actually showing up, not just from… | Leiden Bio Science Park LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choi
YOXLO Revenue, Funding & Valuation Login Get Started YOXLO Revenue Biotechnology Research • • 1-10 Employees View Financials And Employees At YOXLO $ YOXLO revenue & valuation Annual revenue $85,555 Revenue per employee $86,000 Estimated valuation ? This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues $273,776 Total funding No funding Key Contact at YOXLO Stef Verlinden Founder @yoxlo.com View Details View All Employees Overview Emails Format About Employees Insights Funding Tech Stack Trending Companies FAQ Compan
Caroussel 1 - Kingstreet Spring naar content × Business Culinair Overnachten Kunst & Cultuur Lifestyle Langs de kust Tips van de redactie Media Fresca Nieuwsbrief Adverteren Magazine In de media Over ons Charity Zoek Zoek op × Business Culinair Overnachten Kunst & Cultuur Lifestyle Langs de kust Tips van de redactie Media Fresca Nieuwsbrief Adverteren Magazine In de media Over ons Charity O5A3210 O5A3389 O5A3363 O5A3031 O5A2903 Inge van Weert (Voco) en Annerieke Simeone Beleke Bagchus (Amare), Ellen Münninghoff en Hans Passier (Passier Bathrooms & Wellness) Menzo Willems (
YOXLO - Stay Younger for Longer Approach Mission News Funding ← Back to home Approach Mission News Funding ← Back to home What if aging well into your 90s wasn't rare? We believe more people can stay active and independent into their nineties—by slowing aging with science-based interventions. Our approach → Join our mission → If you are reading this, it is because your browser does not support the HTML5 video element. Healthy aging is a lifelong investment Yoxlo’s patented research has unlocked the key to prolonging good health as we age Our approach → Join our mission → Rethinking old age Fro … xplore participation. This page is simply the next step. WHAT HAPPENS AFTER YOU SUBMIT You receive our Founding Member information package. If everything is clear, you can proceed at your own pace. If you prefer to talk things through, we’re happy to schedule a short personal call. No automated payment links. No pressure. Notice: JavaScript is required for this content. Approach Mission News Funding Contact [email protected] Adress YOXLO B.V. Biopartner 5 Building De Limes 7 234